Get the Stockscreener App
2.83
1.43%
0.04
After Hours:
2.93
0.10
+3.53%
Citius Pharmaceuticals Inc stock is traded at $2.83, with a volume of 101.03K.
It is up +1.43% in the last 24 hours and down -27.62% over the past month.
Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. The company is currently advancing four proprietary product candidates namely, LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids, and others.
See More
Previous Close:
$2.79
Open:
$2.83
24h Volume:
101.03K
Relative Volume:
0.38
Market Cap:
$24.32M
Revenue:
-
Net Income/Loss:
$-32.54M
P/E Ratio:
-12.86
EPS:
-0.22
Net Cash Flow:
$-29.06M
1W Performance:
-10.16%
1M Performance:
-27.62%
6M Performance:
-87.84%
1Y Performance:
-81.89%
1-Day Range:
$2.60
$2.90
1-Week Range:
$2.60
$3.40
52-Week Range:
$2.44
$26.75
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Name
Citius Pharmaceuticals Inc
Sector
Industry
Phone
(908) 967-6676
Address
11 COMMERCE DRIVE, CRANFORD, NJ
Compare CTXR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
2.83 | 24.32M | 0 | -32.54M | -29.06M | -0.22 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Upgrade | D. Boral Capital | Hold → Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
Citius Pharmaceuticals Inc Stock (CTXR) Latest News
Amendment: SEC Form 10-K/A filed by Citius Pharmaceuticals Inc. - Quantisnow
Short Interest in Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Expands By 13.6% - Defense World
Citius Pharmaceuticals (STU:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals Completes Registered Direct Offering, Raises $2.7 MillionOn January 7, 2025, Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) announced the closure of a securities purchase agreement with certain institutional investors for a regist - Defense World
Citius Pharmaceuticals’ (CTXR) Buy Rating Reiterated at D. Boral Capital - Defense World
Citius Pharma secures $3 million in direct offering By Investing.com - Investing.com Nigeria
Citius Pharmaceuticals (NASDAQ: CTXR) Announces Progress in LYMPHIR Commercial Launch Preparation - Defense World
Why Citius Pharmaceuticals (CTXR) Stock Is Down 15% - Benzinga
Citius Pharma secures $3 million in direct offering - Investing.com
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - PR Newswire
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharma gears up for LYMPHIR immunotherapy launch By Investing.com - Investing.com Australia
Citius Pharma gears up for LYMPHIR immunotherapy launch - Investing.com
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Oncology Explores Strategic Options with Jefferies Following LYMPHIR FDA Approval - StockTitan
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ:CTXR) Upgraded to “Buy” at D. Boral Capital - Defense World
D. Boral Capital Upgrades Citius Pharmaceuticals (CTXR) - MSN
This American Airlines Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday - Benzinga
American Air upgraded, Nordstrom downgraded: Wall Street's top analyst calls - Yahoo Finance
Citius Pharmaceuticals upgraded by D. Boral Capital with a new price target - Quantisnow
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday - Benzinga
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Re - GuruFocus.com
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Market Sentiment Around Loss-Making Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) - Yahoo Finance
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Rule 5550(a)(2) - Defense World
Citius Pharmaceuticals (NASDAQ:CTXR) Stock Price Down 5.1% – Here’s What Happened - Defense World
Citius Pharmaceuticals stock hits 52-week low at $2.52 By Investing.com - Investing.com Canada
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - The Eastern Progress Online
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
Analysts Hunt for Undervalued Biotech Stocks - Marketscreener.com
Citius Pharmaceuticals (FRA:47N0) Enterprise Value : €9.75 Mil (As of Nov. 28, 2024) - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Earnings Yield (Joel Gree - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) 3-Year EPS without NRI Gr - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Cyclically Adjusted Reven - GuruFocus.com
Citius Pharmaceuticals (FRA:47N0) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com
Hemorrhoids Market Expected to Experience Major Growth by 2032, - openPR
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals Appoints John Laffey to the ARDS Scientific Advisory Board - Marketscreener.com
Citius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK for the Treatment of Cutaneous T-Cell Lymphoma - Marketscreener.com
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids - Marketscreener.com
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals Inc Stock (CTXR) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):